Insulet Corporation
Rank #51HypergrowthPODD · Nasdaq · Healthcare
Insulet Corporation (PODD) — Rank #51 by gross profitability (GP/assets 0.61) · ROE 17.4% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001145197 · all metrics point-in-time as of the filing date.
About
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Show moreShow less
The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors.
Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- insulet.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-18 | 2024-12-31filed 2025-02-21 | 2023-12-31filed 2024-02-23 | 2022-12-31filed 2023-02-24 |
|---|---|---|---|---|
| Assets | ||||
| Cash & equivalents | 716.1 | 953.4 | 704.2 | 689.7 |
| Short-term investments | — | — | — | — |
| Accounts receivable | — | — | — | 140.9 |
| Inventory | 452.6 | 430.4 | 402.6 | 346.8 |
| Total current assets | 1,914.0 | 1,891.3 | 1,582.9 | 1,314.0 |
| Property, plant & equipment, net | — | — | — | 599.9 |
| Goodwill | 51.6 | 51.5 | 51.7 | 51.7 |
| Total assets | 3,190.4 | 3,087.7 | 2,588.2 | 2,251.1 |
| Liabilities | ||||
| Accounts payable | 75.0 | 19.8 | 19.2 | 30.8 |
| Accrued liabilities | — | — | — | 301.0 |
| Deferred revenue | 14.0 | 12.0 | 15.4 | 16.1 |
| Total current liabilities | 680.1 | 528.4 | 451.2 | 364.7 |
| Total debt | 18.4 | 83.8 | 49.4 | 1,401.8 |
| Total liabilities | 1,675.2 | 1,876.1 | 1,855.5 | 1,774.7 |
| Equity | ||||
| Retained earnings | 287.4 | 40.3 | (378.0) | (584.3) |
| Total shareholders' equity | 1,515.2 | 1,211.6 | 732.7 | 476.4 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?